EE04309B1 - Farnesüül-proteiini transferaasi inhibiitorid - Google Patents

Farnesüül-proteiini transferaasi inhibiitorid

Info

Publication number
EE04309B1
EE04309B1 EE9800262A EE9800262A EE04309B1 EE 04309 B1 EE04309 B1 EE 04309B1 EE 9800262 A EE9800262 A EE 9800262A EE 9800262 A EE9800262 A EE 9800262A EE 04309 B1 EE04309 B1 EE 04309B1
Authority
EE
Estonia
Prior art keywords
protein transferase
transferase inhibitors
farnesyl protein
farnesyl
inhibitors
Prior art date
Application number
EE9800262A
Other languages
English (en)
Estonian (et)
Other versions
EE9800262A (et
Inventor
T. Hunt John
Z. Ding Charles
Kim Soong-Hoon
Mitt Toomas
Bhide Rajeev
Leftheris Katerina
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26683350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04309(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of EE9800262A publication Critical patent/EE9800262A/xx
Publication of EE04309B1 publication Critical patent/EE04309B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EE9800262A 1996-02-26 1997-02-24 Farnesüül-proteiini transferaasi inhibiitorid EE04309B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1226596P 1996-02-26 1996-02-26
US2280596P 1996-07-25 1996-07-25
PCT/US1997/002920 WO1997030992A1 (en) 1996-02-26 1997-02-24 Inhibitors of farnesyl protein transferase

Publications (2)

Publication Number Publication Date
EE9800262A EE9800262A (et) 1999-02-15
EE04309B1 true EE04309B1 (et) 2004-06-15

Family

ID=26683350

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800262A EE04309B1 (et) 1996-02-26 1997-02-24 Farnesüül-proteiini transferaasi inhibiitorid

Country Status (24)

Country Link
US (2) US6011029A (bg)
EP (2) EP1481975A1 (bg)
JP (1) JP4115529B2 (bg)
KR (1) KR100522983B1 (bg)
CN (2) CN100376569C (bg)
AU (1) AU718676B2 (bg)
BG (1) BG64951B1 (bg)
BR (1) BR9707614A (bg)
CA (1) CA2239187C (bg)
CZ (1) CZ299762B6 (bg)
EE (1) EE04309B1 (bg)
GE (1) GEP20022616B (bg)
HU (1) HUP9902016A3 (bg)
IL (2) IL124197A (bg)
LV (1) LV12150B (bg)
NO (1) NO319395B1 (bg)
NZ (1) NZ330287A (bg)
PL (1) PL191502B1 (bg)
RO (1) RO121118B1 (bg)
RU (1) RU2225405C2 (bg)
SK (1) SK286568B6 (bg)
TW (1) TW496863B (bg)
UA (1) UA52642C2 (bg)
WO (1) WO1997030992A1 (bg)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117641A (en) 1996-04-11 2000-09-12 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents and uses related thereto
US6727082B1 (en) 1996-04-11 2004-04-27 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
JP2001513622A (ja) 1996-04-11 2001-09-04 マイトティックス インコーポレーテッド 抗菌剤の同定のためのアッセイおよび試薬、並びにそれらに関連する利用
WO1998002436A1 (en) 1996-07-15 1998-01-22 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
WO1999010525A1 (en) * 1997-08-27 1999-03-04 Merck & Co., Inc. A method of treating cancer
JP2001519387A (ja) * 1997-09-29 2001-10-23 ブリストル−マイヤーズ スクイブ カンパニー ファルネシルたんぱく転移酵素のインヒビター
US6458783B1 (en) * 1997-09-29 2002-10-01 Bristol-Myers Squibb Company Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
IL136690A0 (en) * 1997-12-22 2001-06-14 Bayer Ag Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
US6423519B1 (en) 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
US6284755B1 (en) 1998-12-08 2001-09-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6316436B1 (en) 1998-12-08 2001-11-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
CN1219517C (zh) * 1999-01-21 2005-09-21 布里斯托尔-迈尔斯斯奎布公司 RAS－法呢基转移酶抑制剂和磺基丁基醚－7－β－环糊精或2－羟丙基－β－环糊精的复合物及方法
EP1158982A4 (en) * 1999-03-03 2002-06-12 Merck & Co Inc Prenyl protein transferase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CZ302788B6 (cs) 1999-04-15 2011-11-09 Bristol-Myers Squibb Company ´N-(2-Chlor-6-methylfenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolkarboxamid, jeho použití a farmaceutický prostredek s jeho obsahem
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20020115696A1 (en) 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
EP1187605A4 (en) * 1999-06-18 2004-05-26 Thyreos Corp TREATMENT OF NON-MALIGNANT CONDITIONS WITH RAS ANTAGONISTS
US7034055B1 (en) 1999-06-30 2006-04-25 Prescient Neuropharma Inc. 2-aminoindane analogs
FR2796943A1 (fr) * 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
EP1088821A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
US6100395A (en) * 2000-01-10 2000-08-08 Bristol-Myers Squibb Company Reductive alkylation of secondary amines with hydrosilane
DE60130976T2 (de) 2000-02-24 2008-07-17 Janssen Pharmaceutica N.V. Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
EP1283055A4 (en) * 2000-04-07 2003-05-07 Takeda Chemical Industries Ltd SOLUBLE SECRETION PROMOTERS OF THE BETA-AMYOID PROTEIN PRECURSOR
EP1339709B1 (en) * 2000-11-21 2009-06-24 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
WO2002043733A1 (en) * 2000-11-28 2002-06-06 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
PT1351954E (pt) * 2000-12-27 2006-09-29 Janssen Pharmaceutica Nv Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
EP1347966B1 (en) * 2000-12-27 2006-03-08 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US6645966B2 (en) 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
NZ526870A (en) 2001-01-25 2005-11-25 Bristol Myers Squibb Co Methods of administering epothilone analogs for the treatment of cancer
US7759323B2 (en) 2001-05-22 2010-07-20 Eisai R & D Management Co., Ltd. Highly purified antiendotoxin compound
US6905813B2 (en) * 2001-08-29 2005-06-14 Chugai Photo Chemical Co., Ltd. Processing agent for silver halide color photosensitive material and processing method thereof
US20030134846A1 (en) * 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
WO2003041658A2 (en) * 2001-11-13 2003-05-22 Bristol-Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds
EP1580188B9 (en) 2002-02-11 2012-05-23 Bayer HealthCare, LLC Aryl ureas as kinase inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
CN1642422A (zh) * 2002-03-15 2005-07-20 西巴特殊化学品控股有限公司 4－氨基嘧啶及其在表面抗菌处理中的应用
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
AU2003229142A1 (en) * 2002-06-07 2003-12-22 Cortical Pty Ltd Naphthalene derivatives which inhibit the cytokine or biological activity of macrophage inhibitory factor (MIF)
WO2003106628A2 (en) * 2002-06-17 2003-12-24 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase
AU2003259717A1 (en) * 2002-08-07 2004-02-25 Bristol-Myers Squibb Company Modulators of rabggt and methods of use thereof
US7632858B2 (en) * 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
JP2004346059A (ja) * 2003-01-28 2004-12-09 Takeda Chem Ind Ltd 受容体作動薬
CA2514547A1 (en) * 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited Receptor agonists
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
WO2005009961A2 (en) 2003-07-23 2005-02-03 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EP1656156A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Mobilization of hematopoietic cells
EP1656451A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Chimeric peptides for the regulation of gtpases
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US7517890B2 (en) 2003-11-20 2009-04-14 Children's Hospital Medical Center GTPase inhibitors and methods of use
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272068A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. UCH-L1 expression and cancer therapy
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US7323455B2 (en) * 2004-03-24 2008-01-29 Wyeth 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
PT2362218E (pt) * 2004-11-05 2014-12-04 Janssen Pharmaceutica Nv Uso terapêutico de inibidores de farnesiltransferase e métodos para monitorizar a eficácia do mesmo
DK1817013T3 (da) 2004-11-18 2008-10-13 Brystol Myers Squibb Company Enterisk coatet kugle omfattende Ixabepilon
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
JP5009785B2 (ja) * 2005-03-25 2012-08-22 キッセイ薬品工業株式会社 ウレア誘導体、それを含有する医薬組成物およびそれらの医薬用途
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
WO2006113261A2 (en) * 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
DE602006021312D1 (de) * 2005-06-09 2011-05-26 Bristol Myers Squibb Co Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit-protein
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
WO2007016539A2 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
PE20070519A1 (es) * 2005-08-25 2007-07-13 Schering Corp Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
DK1948607T3 (da) 2005-09-16 2010-07-26 Janssen Pharmaceutica Nv Cyclopropylaminer med histamin-H3-receptormodulatorer
EP1955073A2 (en) * 2005-11-15 2008-08-13 Brystol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof
CA2652648C (en) * 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
CA2649736C (en) 2006-04-20 2013-11-26 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
CA2650057C (en) 2006-04-20 2014-07-29 Janssen Pharmaceutica N.V. Phenyl- or pyridinyl-amide as inhibitors of c-fms kinase
RU2009125599A (ru) 2006-12-04 2011-01-20 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс (Us) Композиции и способы лечения рака cpg-богатой днк и купредоксинами
MY147320A (en) 2006-12-14 2012-11-30 Janssen Pharmaceutica Nv Process for the preparation of piperazinyl and diazepanyl benzamide derivatives
WO2008089135A2 (en) * 2007-01-12 2008-07-24 University Of South Florida Identification of biomarkers predictive of dasatinib effects in cancer cells
CA2677803A1 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
AU2008251557B2 (en) * 2007-05-10 2012-12-06 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2008144981A1 (fr) * 2007-05-25 2008-12-04 Topharman Shanghai Co., Ltd. Procédés et intermédiaires pour préparer une 4-acétyl-2,3,4,5-tétrahydro-1h-1,4-benzodiazépine
TW200911262A (en) 2007-06-05 2009-03-16 Schering Corp Novel compounds that are ERK inhibitors
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
SG190620A1 (en) * 2008-05-05 2013-06-28 Sanofi Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2009313927A1 (en) * 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
KR20120087808A (ko) * 2009-05-26 2012-08-07 엑셀리시스, 인코포레이티드 ＰＩ3Ｋ／ｍ ＴＯＲ의 억제제로서의 벤즈옥사제핀 및 이의 사용 및 제조 방법
US8252829B2 (en) 2009-06-05 2012-08-28 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
ES2768990T3 (es) 2009-07-20 2020-06-24 Bristol Myers Squibb Co Combinación de anticuerpos anti-CTLA4 con gemcitabina para el tratamiento sinérgico de enfermedades proliferativas
US8658651B2 (en) 2009-09-30 2014-02-25 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
CA2780333C (en) 2009-11-17 2016-05-24 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
AU2011236155B2 (en) * 2010-04-06 2014-01-16 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and method for producing same
AU2014201038B2 (en) * 2010-04-06 2015-08-06 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and method for producing same
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
BR112013018534B1 (pt) 2011-01-20 2021-04-06 Board Of Regents, The University Of Texas System Agente de contraste, seus métodos de preparação, e produto de combinação
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
CN104684919A (zh) 2012-07-31 2015-06-03 陶氏环球技术有限责任公司 制备烯烃聚合催化剂活化剂的方法
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
CN104768962B (zh) 2012-11-17 2017-04-05 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
JP6473133B2 (ja) * 2013-03-15 2019-02-20 アラクセス ファーマ エルエルシー Ｋｒａｓｇ１２ｃの共有結合性阻害剤
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
SG10201806498RA (en) 2014-06-27 2018-08-30 Univ California Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
KR20180005178A (ko) 2015-04-10 2018-01-15 아락세스 파마 엘엘씨 치환된 퀴나졸린 화합물 및 이의 사용방법
WO2016168540A1 (en) 2015-04-15 2016-10-20 Araxes Pharma Llc Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
SI3385395T1 (sl) 2015-08-17 2020-07-31 Kura Oncology, Inc. Metode zdravljenja rakavih pacientov s farnezil transferaznimi inhibitorji
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
TW201726656A (zh) 2015-11-16 2017-08-01 亞瑞克西斯製藥公司 包含經取代雜環基團之２－經取代喹唑啉化合物及其使用方法
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
EP3464270B1 (en) * 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
JP2019534260A (ja) 2016-10-07 2019-11-28 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤としての複素環式化合物およびその使用方法
MX2019005065A (es) 2016-11-03 2019-08-21 Kura Oncology Inc Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa.
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
CA3053795A1 (en) 2017-02-21 2018-08-30 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR20200010306A (ko) 2017-05-25 2020-01-30 아락세스 파마 엘엘씨 Kras의 공유적 억제제
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
US10736897B2 (en) 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
MY200746A (en) 2017-08-07 2024-01-13 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2019055877A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CA3105099A1 (en) 2018-06-29 2020-01-02 Forma Therapeutics, Inc. Inhibiting creb binding protein (cbp)
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
EP3873469A2 (en) 2018-11-01 2021-09-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3124616A1 (en) 2018-12-21 2020-06-25 Kura Oncology, Inc. Therapies for squamous cell carcinomas
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
WO2020190604A1 (en) 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
AU2020254492A1 (en) 2019-03-29 2021-11-11 Kura Oncology, Inc. Methods of treating Squamous Cell Carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
AU2020279253A1 (en) * 2019-05-20 2021-12-16 1200 Pharma Llc KRAS G12C inhibitors and uses thereof
CN115667504A (zh) 2020-04-27 2023-01-31 诺华股份有限公司 用于眼细胞疗法的方法和组合物
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
CN115745960B (zh) * 2021-09-02 2024-08-30 中国科学院上海药物研究所 一类含喹啉酮酰胺的化合物及其制备方法、药物组合物和用途
CN114230529A (zh) * 2021-11-03 2022-03-25 河南大学 四氢喹喔啉磺酰胺衍生物及其制备方法与用途
CN118556044A (zh) * 2022-01-29 2024-08-27 江苏恒瑞医药股份有限公司 稠杂环类化合物、其制备方法及其在医药上的应用
WO2024097606A1 (en) * 2022-10-31 2024-05-10 Eli Lilly And Company Ahr agonists

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1923821A1 (de) * 1969-05-09 1970-11-19 Wuelfing J A Fa 1,2,4,5-Tetrahydro-[3H]-benzo-1,4-diazepin-2,5-dion-Derivate,Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneipraeparaten
JPS6168487A (ja) * 1984-09-12 1986-04-08 Sumitomo Chem Co Ltd カルバモイルアゾール誘導体およびそれを有効成分とする除草剤
EP0322779A3 (en) * 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolactam compounds and pharmaceutical uses thereof
JP2729545B2 (ja) 1991-06-05 1998-03-18 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料用の処理液及びそれを用いた処理方法
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
SG90035A1 (en) * 1992-12-21 2002-07-23 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
AU6219994A (en) * 1993-03-11 1994-09-26 Yamanouchi Pharmaceutical Co., Ltd. Compound with vasopressin antagonism
CA2118985A1 (en) * 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
US5441952A (en) * 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
EP0698015A1 (en) 1993-05-14 1996-02-28 Genentech, Inc. Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
WO1995012612A1 (en) * 1993-11-05 1995-05-11 Warner-Lambert Company Substituted di- and tripeptide inhibitors of protein:farnesyl transferase
US5753650A (en) * 1994-05-20 1998-05-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
BR9508178A (pt) * 1994-06-29 1997-11-18 Smithkline Beecham Corp Antagonistas de receptor de vitronectina
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
EP1007525A1 (en) 1997-08-29 2000-06-14 Zeneca Limited Aminometyl oxooxazolidinyl benzene derivatives

Also Published As

Publication number Publication date
RU2225405C2 (ru) 2004-03-10
CZ299762B6 (cs) 2008-11-12
SK286568B6 (sk) 2009-01-07
KR19990087250A (ko) 1999-12-15
PL191502B1 (pl) 2006-05-31
IL124197A (en) 2003-06-24
CA2239187A1 (en) 1997-08-28
HUP9902016A3 (en) 2000-02-28
WO1997030992A1 (en) 1997-08-28
SK117398A3 (en) 2000-12-11
JP4115529B2 (ja) 2008-07-09
CN100376569C (zh) 2008-03-26
NO319395B1 (no) 2005-08-08
BR9707614A (pt) 1999-07-27
IL141908A (en) 2003-04-10
US6011029A (en) 2000-01-04
TW496863B (en) 2002-08-01
LV12150A (lv) 1998-10-20
NZ330287A (en) 2000-03-27
EP0892797A4 (en) 2004-10-20
CZ269698A3 (cs) 1999-10-13
EP1481975A1 (en) 2004-12-01
EE9800262A (et) 1999-02-15
IL141908A0 (en) 2002-03-10
BG64951B1 (bg) 2006-10-31
KR100522983B1 (ko) 2006-09-20
CN1347881A (zh) 2002-05-08
CA2239187C (en) 2003-04-22
GEP20022616B (en) 2002-01-25
UA52642C2 (uk) 2003-01-15
NO983892L (no) 1998-08-25
NO983892D0 (no) 1998-08-25
EP0892797A1 (en) 1999-01-27
RO121118B1 (ro) 2006-12-29
US6455523B1 (en) 2002-09-24
LV12150B (en) 1998-12-20
BG102738A (bg) 1999-09-30
HUP9902016A2 (hu) 1999-09-28
AU2136697A (en) 1997-09-10
JP2000502356A (ja) 2000-02-29
CN1214685A (zh) 1999-04-21
AU718676B2 (en) 2000-04-20
PL328868A1 (en) 1999-03-01

Similar Documents

Publication Publication Date Title
EE04309B1 (et) Farnesüül-proteiini transferaasi inhibiitorid
EE9800408A (et) Proteiinfarnesüültransferaasi inhibiitorid
NO996571D0 (no) Inhibitorer for farnesyl-protein-transferase
EE9700314A (et) Farnesüül-proteiini transferaasi inhibiitorid
FI951554A (fi) Imidatsolipitoisia farnesyyliproteiinitransferaasi-inhibiittoreita
FI952010A (fi) Farnesyyliproteiinitransferaasin estäjät
EE9800146A (et) Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid
EP0918771A4 (en) THIADIOXOBENZODIAZEPINES FOR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
NO963860D0 (no) Isoprenyl-transferase-inhibitorer
DE69924876D1 (de) Farnesyl protein transferase inhibitoren
EP1027042A4 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS
AU4020897A (en) 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
NO20012961D0 (no) Trisykliske farnesylproteintransferase-inhibitorer
ATE214367T1 (de) Farnesyl transferase inhibitoren
AU4329397A (en) Semipeptoid farnesyl protein transferase inhibitors and analogs thereof
ZA971621B (en) Inhibitors of farnesyl protein transferase
HUP9903221A3 (en) Inhibitors of protein farnesyl transferase

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20140224